In human breast cancer, we have previously shown that the SFRP1 and SFRP5 promoter is epigenetically silenced in 61% and 73% of invasive breast carcinomas, respectively, each of which was associated with unfavorable patient prognosis [27,28]. Here, SFRP5 is linked to breast cancer.